Reviews, book chapters and correspondence

60 Labrijn, A.F., M.L. Janmaat, J.M. Reichert and P.W.H.I. Parren. 2019. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Jun 7. doi: 10.1038/s41573-019-0028-1. [Epub ahead of print] Review

59 Engelberts, P.J., E.C.W. Breij, T. Valerius, J. Schuurman, P.W.H.I. Parren and F.J. Beurskens. 2018. Response to Comment on "Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells". J. Immunol.200:2517.

58 Janmaat, M.L., N.W.C.J. van de Donk, J. Lammerts van Bueren, T. Ahmadi, A.K. Sasser, R.K. Jansson, H.M. Lokhorst and P.W.H.I. Parren. 2018. Discovery, development and mechanisms of action of the human CD38 antibody daratumumab. Successful Drug Discovery, Volume 3, in Press.

57 P.W.H.I. Parren and J.S. Huston. 2017. Celebrating Antibody Therapeutics. Protein Eng. Des. Sel. 30:573. doi: 10.1093/protein/gzx053.

56 Parren P.W.H.I., P.J. Carter PJ and A. Plückthun. 2017. Changes to International NonProprietary Names for antibody therapeutics 2017 and beyond: of mice, men and more. MAbs. 9:898-906.

55 Labrijn A.F. and P.W.H.I. Parren. 2016. Hitting Ebola: to the power of two. Science 354:284-285.

54 Larrick J.W., M.R. Alfenito, J.K. Scott, P.W.H.I. Parren, D.R. Burton, A.R. Bradbury, C.A. Lemere, A. Messer, J.S. Huston, P.J. Carter, T. Veldman, K.A. Chester, J. Schuurman, G.P. Adams and J.M. Reichert. 2016. Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11-15, 2016, San Diego, CA. MAbs. 24:1-10.

53 Schuurman, J. and P.W.H.I. Parren. 2016. What’s in store for antibody therapy (editorial). Current Opin. Immunol. 40: vii-xiii.

52 Van de Donk, N.W.C.J., M.L. Janmaat, T. Mutis, J.J. Lammerts van Bueren, H.M. Lokhorst and P.W.H.I. Parren. 2016. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol. Reviews 270: 95-112.

51 Jones T.D., P.J. Carter, A. Plückthun, M. Vásquez, R.G. Holgate, I. Hötzel, A.G. Popplewell, P.W.H.I. Parren, M. Enzelberger, H.H. Rademaker, M.R. Clark, D.C. Lowe, B.I. Dahiyat, V. Smith, J.M. Lambert, H. Wu, M. Reilly, J.S. Haurum, S. Dübel, J.S. Huston, T. Schirrmann, R.A. Janssen, M. Steegmaier, J.A. Gross, A.R. Bradbury, D.R. Burton, D.S. Dimitrov, K.A. Chester, M.J. Glennie, J. Davies, A. Walker, S. Martin, J. McCafferty and M.P. Baker. The INNs and outs of antibody nonproprietary names. MAbs 8: 1-9, 2016.

50 Parren P.W.H.I., D.R. Burton, A. Bradbury, J.S. Huston, P.J. Carter, T. Veldman, K.A. Chester, J.W. Larrick, M.R. Alfenito, J.K. Scott, L.M. Weiner, G.P. Adams and J.M. Reichert. Antibody Engineering & Therapeutics 2015: The Antibody Society's annual meeting December 7-10, 2015, San Diego, CA. MAbs 7: 981-988, 2015.

49 Melis JP, K. Strumane, S.R. Ruuls, F.J. Beurskens, J. Schuurman and P.W.H.I. Parren. 2015. Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics. Mol. Immunol. 67: 117-130.

48 Bradbury, A. and A. Plückthun and 110 cosignatories. 2015. Standardize antibodies used in research. Nature 518:27-29.

47 Larrick, J.W., P.W.H.I. Parren, J.S. Huston, A. Pluckthun, I.M. Tomlinson, K.A. Chester, D.R. Burton, G.P. Adams, L.M. Weiner, J.K. Scott, M.R. Alfenito, T. Veldman and J.M Reichert. 2014. Antibody engineering and therapeutics conference. The annual meeting of the antibody society, Huntington Beach, CA, December 7–11, 2014. MAbs 6:1115-1123.

46 Schuurman J, Y.F. Graus, A.F. Labrijn, S. Ruuls and P.W.H.I. Parren.2014. Opening the door to innovation. MAbs. 6:812-819.

45 Almagro JC, G.L. Gilliland, F. Breden, J. Scott, D. Sok, M. Pauthner,J.M.  Reichert, G. Helguera, R. Andrabi, R. Mabry, M. Bléry, J.E. Voss, J. Laurén, L. Abuqayyas, S. Barghorn, E. Ben-Jacob, J.E.  Crowe, J.S. Huston, S.A. Johnston, E. Krauland, F. Lund-Johansen, W.A. Marasco, P.W.H.I. Parren and K.Y. Xu. 2014. Antibody Engineering and Therapeutics: December 8-12, 2013, Huntington Beach, CA. MAbs 6:577-618.

44 Schuurman J. and P.W.H.I. Parren. 2014. Mind the Gap. Methods. 65:1-4.

43 Overdijk, M.B., S. Verploegen, W.K. Bleeker and P.W.H.I. Parren. 2014. Chapter 13. Role of IgG Fc receptors in monoclonal antibody therapy of cancer. In: Antibody Fc: Linking adaptive and innate immunity. M.E. Ackerman and F. Nimmerjahn eds. Elsevier, Amsterdam. pp. 239-255.

42 Lindorfer, M.A., J, Bakker, P.W.H.I. Parren and R.P. Taylor. 2014. Chapter 63: Ofatumumab: a next-generation human therapeutic CD20 antibody with potent complement-dependent cytotoxicity. Handbook of Therapeutic Antibodies. S. Dübel and J.M. Reichert eds. Wiley-VCH Verlag GmbH & Co, Weinberg, Germany. pp 1733-1774.

41 Parren, P.W.H.I. and A.A. Lugovskoy. 2013. Therapeutic antibody engineering: Current and future advances driving the strongest growth area in the pharmaceutical industry. MAbs 5:175-177.

40 Schuurman, J., A.F. Labrijn and P.W.H.I. Parren. 2012. Fab-arm exchange: What's in a name? (correspondence)  MAbs 4:636.

39 Lammerts van Bueren, J.J., W.K. Bleeker, A. Brännström, M. Jansson, M. Peipp, T. Schneider-Merck, T. Valerius, J.G.J. van de Winkel and P.W.H.I. Parren. Retraction. 2012. Proc. Natl. Acad. Sci. USA 109: 5548. (retraction of Lammerts van Bueren, J.J., W.K. Bleeker, A. Brännström, A. von Euler, M. Jansson, M. Peipp, T. Schneider-Merck, T. Valerius, J.G.J. van de Winkel and P.W.H.I. Parren. 2008. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and inter-molecular flexibility. Proc. Natl. Acad. Sci. USA 105:6109-6114).

38 Labrijn, A.F., J. Schuurman, J.G.J. van de Winkel and P.W.H.I. Parren. 2010. Reply to Fab Arm exchange (correspondence). Nature Biotechnology 28: 125-126.

37 Timmerman, P., W.C. Puijk, R. Boshuizen, P. van Dijken, J.W. Slootstra, F.J. Beurskens, P.W.H.I. Parren, A. Huber, M.F. Bachmann and R.H. Meloen. 2009. Functional reconstruction of structurally complex epitopes using CLIPSTM technology.  The Open Vaccine Journal 2: 56-67.

36 Parren, P.W.H.I. and D.R. Burton. 2009. Two-in-one designer antibodies. Science 323: 1567-1568.

35 Parren, P.W.H.I. and J.G.J. van de Winkel. 2008. An integrated science-based approach to drug development. (editorial) Current Opin. Immunol. 20: 426-430.

34 Ruuls, S., J.J. Lammerts van Bueren, J.G.J. van de Winkel and P.W.H.I. Parren. 2008. Novel human antibody therapeutics: the age of the Umabs. Biotechnology J. 3:1157-1171.

33 Losen, M., P.Martínez-Martínez, M. Phernambucq, J. Schuurman, P.W.H.I. Parren and M.H. De Baets. 2008. Treatment of myasthenia gravis by preventing acetylcholine receptor modulation. Ann. N.Y. Acad. Sci. 1132: 174-179.

32 Boot, E.P. and P.W.H.I. Parren. 2008. Genetic vaccination: one-shot shopping for immediate and sustained protection. Mol. Therapy 16:6-7.

31 Van Walle, I., Y. Gansemans, P.W.H.I. Parren, P. Stas, and I. Lasters. 2007. Immunogenicity screening in protein drug development. Expert Opin. Biol. Ther. 7: 405-418.

30 Bakker, J.M., W.K. Bleeker, P.W.H.I. Parren. 2004. Therapeutic antibody gene transfer: An active approach to passive immunity. Mol. Therapy 10: 411-416.

29 Stassen, M.H., B.M. Machiels, E. Fostieri, S.J. Tzartos, S. Berrih-Aknin, E. Bosmans, P.W.H.I. Parren and M.H. de Baets. 2003. Characterization of a fully human IgG1 reconstructed from an anti-AChR Fab. Ann. N. Y. Acad. Sci. 998:399-400.

28 Ollmann Saphire, E., R.L. Stanfield, M.D.M. Crispin, G. Morris,  M.B. Zwick,, R.A. Pantophlet, P.W.H.I. Parren, P.M. Rudd, R.A. Dwek, D.R. Burton and I.A. Wilson. 2003. Crystal structure of an intact Human IgG: antibody asymmetry, flexibility, and a guide for HIV-1 vaccine design. Adv.Exp.Med.Biol. 535:55-66.

27 Parren, P.W.H.I., J.H.W. Leusen and J.G.J. van de Winkel. 2003. Catalytic antibodies: state-of-the-art immunity or ancient history? Trends Immunol.24: 467-469.

26 Ollmann Saphire, E., R.L. Stanfield, M.D.M. Crispin, P.W.H.I. Parren, P.M. Rudd, R.A. Dwek, D.R. Burton and I.A. Wilson. 2002. Contrasting IgG structures reveal extreme asymmetry and flexibility. J. Mol. Biol. 319: 9-18.

25 Ollmann Saphire, E. and P.W.H.I. Parren. 2001. Listening for virus infection. Nature Biotechnology [News and Views]. 19:823-824.

24 Moore, J.P., P.W.H.I. Parren, and D.R. Burton.  2001.  Genetic subtypes, humoral immunity and HIV-1 vaccine development. J. Virol. 75:5721-5729.

23 Ollmann Saphire, E., D.R. Burton, P.W.H.I. Parren, I. Wilson.  2001.  A new look at rheumatoid factor.  Cutting Edge Reports.  Rheuma 21st Century Ltd, Brooklyn, NY.

22 Burton, D.R., E. Ollmann Saphire, and P.W.H.I. Parren. 2001. A model for neutralization of viruses based on antibody coating of the virion surface. Current Topics Microbiol.Immunol. 260:109-143.

21 Poignard, P., E.Ollmann Saphire, P.W.H.I. Parren and D.R. Burton.  2001. Gp120: biologic aspects of structural features.  Ann. Rev. Immunol.  19:253-274.

20 Parren, P.W.H.I, and D.R. Burton. 2001. The anti-viral activity of antibodies in vitro and in vivo. Adv. Immunol, 77:195-262.

19 Burton, D.R., P.W.H.I. Parren.  2000.  Fighting the Ebola virus, Nature, 408:527-528. [News and Views].

18 Burton, D.R., R.A. Williamson, P.W.H.I. Parren, 2000. Antibody and virus; binding and neutralization. Virology, 270: 1-3.

17 Parren, P.W.H.I., P. Poignard, H.J. Ditzel, R.A. Williamson, and D.R. Burton. 2000. Antibodies in human infectious disease. Immunologic Research, 21:265-278, 2000.

16 Parren, P.W.H.I., D.R. Burton, Q.J. Sattentau, 2000.  Mechanisms and in vivo significance of HIV-1 neutralization, AIDS Pathogenesis, H. Schuitemaker and F. Miedema, Eds., Chapter 7, Kluwer Academic Publishers, Dordrecht, The Netherlands, pp. 99-132.

15 Labrijn, A.F., and P.W.H.I. Parren. 1999. Neutralizing epitopes of HIV-1. In: HIV Molecular Immunology Database. B.T.M. Korber, B.F. Haynes, R. Koup, C. Brander, J.P. Moore and B.D. Walker Eds. Los Alamos National Laboratory, Los Alamos, NM. [].

14 Parren P.W.H.I., J.P. Moore, Dennis R. Burton, and Quentin J. Sattentau. 1999.  The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity. AIDS, 13 suppl A: S137-S162.

13 Maruyama, T., P.W.H.I. Parren, A. Sanchez, I. Rensink, L.L. Rodriguez, A. Khan, C.J. Peters, and D.R. Burton. 1999. Recombinant human monoclonal antibodies to Ebola virus. J. Infect. Dis. 179 Suppl 1: S235-239.

12 Maruyama, T., M. J. Buchmeier, P.W.H.I. Parren, and D. R. Burton. 1998. Ebola virus, neutrophils, and antibody specificity. (Technical comment). Science 282: 843. [ 282/5390/843a].

11 Burton, D. R., P.W.H.I. Parren, P. Poignard, D. E. Mosier, M. C. Gauduin and R. A. Koup. 1998. The activity of a potent neutralizing human antibody against primary isolates in vivo. In: Retroviruses of human AIDS and related animal diseases. Onzième Colloque des Cent Gardes. M. Girard and B. Dodet eds., Elsevier, Amsterdam, the Netherlands. pp. 127-130.

10 Ugolini, S., I. Mondor, M. Moulard, P.J. Klasse, P.W.H.I. Parren, D.R. Burton, and Q.J. Sattentau. 1998. HIV-1-CD4-coreceptor interactions in virus binding and neutralization. In: Retroviruses of human AIDS and related animal diseases. Onzième Colloque des Cent Gardes. M. Girard and B. Dodet eds., Elsevier, Amsterdam, the Netherlands. pp. 85-91.

9 Glamann, J., P.W.H.I. Parren, H. Ditzel, C. Arnold, K.A. Kent, D. Montefiori, D. Burton, and V.M. Hirsch. 1997. Characterization of SIV envelope-specific Fabs obtained by combinatorial antibody cloning from a long-term nonprogressor macaque. In: Vaccines 97. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, NY. pp 299-303.

7 Parren, P.W.H.I., M.-C. Gauduin, R.A. Koup, P. Poignard, Q.J. Sattentau, P. Fisicaro, and D.R. Burton. 1997. Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. Immunol. Letters 57: 105-112.

6 Parren, P.W.H.I., Q. J. Sattentau, and D.R. Burton. 1997. Importance of anti-HIV-1 antibodies (reply). Nature Med. 3:591, 1997.

5 Parren, P.W.H.I. and D.R. Burton. 1997. Antibodies against HIV-1 from phage display libraries: mapping of an immune response and progress towards anti-viral immunotherapy. Chem. Immunol. 65: 18-56.

4 Parren, P.W.H.I., P. Fisicaro, C.F. Barbas III, and D.R. Burton. 1996. Antibody and HIV-1: Neutralization in vitro and protection in vivo. In:  Antibody Engineering, Chapter 1.3. C.A. Thibeault and L.M. Savage eds. IBC Biomedical Library Series, Southborough, MA, pp 48-63.

3 Parren, P.W.H.I., C.F. Barbas III, and D.R. Burton. 1995. Neutralization of HIV-1 by antibody, the b12 epitope. J. NIH Res. 7:49-50.

2 Burton, D.R., C.F. Barbas, J.M. Binley, H.J. Ditzel, and P.W.H.I. Parren. 1994. Recombinant human neutralizing antibodies to HIV-1. In: Retroviruses of human AIDS and related animal diseases, Neuvieme colloque des cents gardes. M. Girard and B. Dodet eds. Fondation Marcel Merieux, Lyon, France, pp 167-175.

1 Parren, P.W.H.I. 1992. Preparation of genetically engineered monoclonal antibodies for human immunotherapy. Hum. Antibod. Hybridomas 3:137-145.